Videx

See also: Generic Videx EC

Videx is a brand name of didanosine, approved by the FDA in the following formulation(s):

VIDEX (didanosine - for solution; oral)

• 
  Manufacturer: BRISTOL MYERS SQUIBB
  
  Approval date: October 9, 1991
  
  Strength(s): 10MG/ML ^[RLD][AA]

Has a generic version of Videx been approved?

A generic version of Videx has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Videx and have been approved by the FDA:

didanosine for solution; oral

• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: March 8, 2007
  
  Strength(s): 10MG/ML ^[AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Videx. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Oral dosing formulations of dideoxy purine nucleosides
  Patent 5,880,106
  Issued: March 9, 1999
  Inventor(s): Ullah; Ismat & Agharkar; Shreeram Narahari & Wiley; Gary James
  Assignee(s): Bristol-Myers Squibb Company
  Improved oral dosage formulations for acid-labile dideoxy purine nucleoside derivatives such as ddA, ddI, and ddG, have been developed by incorporating selected water-insoluble buffering systems in the formulation. These novel formulations provide reduced mass dosage units in the form of convenient, palatable chewable/dispersible tablets or a dry powder sachet. The reduced mass requirement, necessary to allow tablets of reasonable size, was achieved in part by an unexpected 20 to 25% increase in drug bioavailability resulting from use of the selected buffering systems comprised of an insoluble magnesium antacid agent and either dihydroxyaluminum sodium carbonate or calcium carbonate.
  
  Patent expiration dates:
  
  
  • July 22, 2011
    
  
  
  
  • January 22, 2012
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Videx Chewable/Dispersible Buffered Tablets Consumer Information (Wolters Kluwer)
• Videx Powder Pack Consumer Information (Wolters Kluwer)
• Videx Solution Consumer Information (Wolters Kluwer)
• Videx Consumer Information (Cerner Multum)
• Videx Advanced Consumer Information (Micromedex)
• Videx AHFS DI Monographs (ASHP)
• Didanosine Chewable/Dispersible Buffered Tablets Consumer Information (Wolters Kluwer)
• Didanosine Delayed-Release Enteric-Coated Capsules Consumer Information (Wolters Kluwer)
• Didanosine Powder Pack Consumer Information (Wolters Kluwer)
• Didanosine Solution Consumer Information (Wolters Kluwer)
• Didanosine Consumer Information (Cerner Multum)
• Videx Pediatric Advanced Consumer Information (Micromedex)
• Didanosine Advanced Consumer Information (Micromedex)
• Didanosine AHFS DI Monographs (ASHP)